217 related articles for article (PubMed ID: 37700806)
1. Targeting
Elhariri A; Alhaj A; Ahn D; Sonbol MB; Bekaii-Saab T; Wu C; Rutenberg MS; Stauffer J; Starr J; Majeed U; Jones J; Borad M; Babiker H
World J Clin Oncol; 2023 Aug; 14(8):285-296. PubMed ID: 37700806
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
3. Sensitive Detection of KRAS Mutations by Clustered Regularly Interspaced Short Palindromic Repeats.
Zhou H; Tsou JH; Leng Q; Jiang F
Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33467412
[TBL] [Abstract][Full Text] [Related]
4. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
[TBL] [Abstract][Full Text] [Related]
6. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
Rafael D; Montero S; Carcavilla P; Andrade F; German-Cortés J; Diaz-Riascos ZV; Seras-Franzoso J; Llaguno M; Fernández B; Pereira A; Duran-Lara EF; Schwartz S; Abasolo I
ACS Appl Mater Interfaces; 2023 Mar; 15(8):10398-10413. PubMed ID: 36795046
[TBL] [Abstract][Full Text] [Related]
7. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
8. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Gillson J; Ramaswamy Y; Singh G; Gorfe AA; Pavlakis N; Samra J; Mittal A; Sahni S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456277
[TBL] [Abstract][Full Text] [Related]
10. Annual review of KRAS inhibitors in 2022.
Wang H; Chi L; Yu F; Dai H; Gao C; Si X; Wang Z; Liu L; Zheng J; Shan L; Liu H; Zhang Q
Eur J Med Chem; 2023 Mar; 249():115124. PubMed ID: 36680986
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS in Non-Small Cell Lung Cancer.
Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
Front Oncol; 2021; 11():792635. PubMed ID: 35083149
[TBL] [Abstract][Full Text] [Related]
12. The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers.
Andrade F; German-Cortés J; Montero S; Carcavilla P; Baranda-Martínez-Abascal D; Moltó-Abad M; Seras-Franzoso J; Díaz-Riascos ZV; Rafael D; Abasolo I
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376135
[TBL] [Abstract][Full Text] [Related]
13. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors.
Zhou X; Ji Y; Zhou J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110848
[TBL] [Abstract][Full Text] [Related]
14. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.
Boby JM; Mohd Ghazali NN; Mani A; George M
J Med Case Rep; 2022 Nov; 16(1):420. PubMed ID: 36329437
[TBL] [Abstract][Full Text] [Related]
15. Targeting RAS - will GPR31 deliver us a new path forward?
Fehrenbacher N; Philips MR
Mol Cell Oncol; 2017; 4(6):e1359228. PubMed ID: 29209647
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
17. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
18. Targeting Mutated KRAS Genes to Treat Solid Tumours.
Krishnan T; Roberts-Thomson R; Broadbridge V; Price T
Mol Diagn Ther; 2022 Jan; 26(1):39-49. PubMed ID: 34914038
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
[No Abstract] [Full Text] [Related]
20. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
